Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasm Metastasis | 4 | 2020 | 165 | 1.120 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2020 | 121 | 1.050 |
Why?
|
| Apelin Receptors | 2 | 2021 | 11 | 0.760 |
Why?
|
| Ovarian Neoplasms | 3 | 2025 | 607 | 0.640 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2017 | 5 | 0.530 |
Why?
|
| Paracrine Communication | 1 | 2017 | 17 | 0.520 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 484 | 0.480 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 141 | 0.400 |
Why?
|
| Cell Line, Tumor | 6 | 2023 | 1360 | 0.320 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2023 | 472 | 0.240 |
Why?
|
| Carcinosarcoma | 1 | 2025 | 31 | 0.230 |
Why?
|
| Uterine Neoplasms | 1 | 2025 | 80 | 0.220 |
Why?
|
| Homeodomain Proteins | 2 | 2023 | 79 | 0.210 |
Why?
|
| Cell Proliferation | 4 | 2021 | 827 | 0.210 |
Why?
|
| Mice, Nude | 3 | 2021 | 333 | 0.210 |
Why?
|
| Sarcoma, Ewing | 1 | 2023 | 15 | 0.200 |
Why?
|
| Esophagitis | 1 | 2023 | 7 | 0.200 |
Why?
|
| Esophageal Diseases | 1 | 2023 | 13 | 0.190 |
Why?
|
| Cell Movement | 3 | 2020 | 377 | 0.190 |
Why?
|
| Herpes Simplex | 1 | 2023 | 20 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 348 | 0.190 |
Why?
|
| STAT3 Transcription Factor | 2 | 2021 | 97 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 433 | 0.180 |
Why?
|
| Cell Adhesion | 2 | 2019 | 139 | 0.170 |
Why?
|
| Apelin | 1 | 2021 | 5 | 0.170 |
Why?
|
| Neuropilin-2 | 1 | 2020 | 1 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2020 | 1 | 0.170 |
Why?
|
| Peritoneal Neoplasms | 1 | 2021 | 80 | 0.160 |
Why?
|
| Humans | 11 | 2025 | 29078 | 0.160 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 159 | 0.150 |
Why?
|
| Animals | 6 | 2021 | 10756 | 0.150 |
Why?
|
| Female | 7 | 2025 | 15740 | 0.150 |
Why?
|
| Nitrobenzoates | 1 | 2019 | 7 | 0.150 |
Why?
|
| Pyrans | 1 | 2019 | 8 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 95 | 0.140 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 117 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 415 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 158 | 0.140 |
Why?
|
| Signal Transduction | 3 | 2020 | 1482 | 0.140 |
Why?
|
| Veratrum Alkaloids | 1 | 2017 | 4 | 0.130 |
Why?
|
| Mice, SCID | 1 | 2017 | 60 | 0.130 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 50 | 0.130 |
Why?
|
| Heterografts | 1 | 2017 | 66 | 0.130 |
Why?
|
| Disease Progression | 1 | 2019 | 481 | 0.130 |
Why?
|
| Basigin | 1 | 2017 | 3 | 0.130 |
Why?
|
| Cell Line | 1 | 2019 | 701 | 0.130 |
Why?
|
| Cellular Reprogramming | 1 | 2017 | 11 | 0.130 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 31 | 0.120 |
Why?
|
| Pyridines | 1 | 2017 | 108 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2017 | 128 | 0.120 |
Why?
|
| Membrane Transport Proteins | 1 | 2017 | 79 | 0.120 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 203 | 0.110 |
Why?
|
| Twist-Related Protein 1 | 1 | 2015 | 5 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2017 | 216 | 0.110 |
Why?
|
| Mice | 3 | 2021 | 4845 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 120 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 249 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2014 | 428 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2015 | 303 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 556 | 0.080 |
Why?
|
| Neoplasms | 1 | 2016 | 882 | 0.060 |
Why?
|
| Quinolines | 1 | 2025 | 35 | 0.060 |
Why?
|
| Carboplatin | 1 | 2025 | 121 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2025 | 80 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2025 | 226 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2025 | 201 | 0.050 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2023 | 7 | 0.050 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2023 | 8 | 0.050 |
Why?
|
| Integrins | 1 | 2023 | 29 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 25 | 0.050 |
Why?
|
| Simplexvirus | 1 | 2023 | 5 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2023 | 82 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2023 | 32 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 191 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 314 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2021 | 163 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2020 | 35 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 276 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2023 | 645 | 0.040 |
Why?
|
| Lipids | 1 | 2021 | 220 | 0.040 |
Why?
|
| Apoptosis | 1 | 2021 | 781 | 0.030 |
Why?
|
| Plasma Membrane Calcium-Transporting ATPases | 1 | 2017 | 2 | 0.030 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2017 | 4 | 0.030 |
Why?
|
| Child | 1 | 2023 | 2335 | 0.030 |
Why?
|
| Proteolysis | 1 | 2017 | 59 | 0.030 |
Why?
|
| Clone Cells | 1 | 2016 | 22 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 137 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2017 | 111 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2017 | 80 | 0.030 |
Why?
|
| Calcium Signaling | 1 | 2017 | 72 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 94 | 0.030 |
Why?
|
| Amino Acids | 1 | 2017 | 85 | 0.030 |
Why?
|
| Transfection | 1 | 2017 | 319 | 0.030 |
Why?
|
| Aged | 1 | 2025 | 5627 | 0.030 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2015 | 20 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 26 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 171 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 667 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2015 | 202 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 247 | 0.030 |
Why?
|
| Middle Aged | 1 | 2025 | 7458 | 0.030 |
Why?
|
| Models, Biological | 1 | 2016 | 471 | 0.030 |
Why?
|
| Adult | 1 | 2025 | 8080 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 1619 | 0.020 |
Why?
|